Hypertension Market

• The hypertension market is projected to witness consistent growth throughout the forecast period (2023–2032) due to the increasing global prevalence of hypertension. This prevalence increase fuels a growing demand for treatment options that effectively address hypertension and its complications.
• According to analysts at DelveInsight, there has been a notable rise in the market size of hypertension in recent years. This increase is driven by advancements in research and development, which have introduced innovative drugs and therapies for hypertension.
• To drive the market growth, Hypertension companies like Mineralys Therapeutics Inc, CinCor Pharma, and others are evaluating their assets in the mid-late stage of development. With the expected approval of these therapies during the forecast period [2023–2032, the overall therapeutic market of hypertension will likely rise at a significant CAGR].

DelveInsight’s report titled “Hypertension Market Insights, Epidemiology, and Market Forecast 2032” comprehensively analyzes hypertension. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of hypertension egmented by gender-specific, age-specific, and severity-specific cases. The Hypertension market report offers an in-depth understanding of the various aspects related to the patient population, including diagnosis, prescriptions patterns, physician perspectives, market access, treatment, and future market developments for the seven major markets, including the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2019 to 2032.

The report discusses current Hypertension treatment practices, algorithms, and unmet medical needs to gauge the market’s overall potential and identify business opportunities.

Hypertension Overview

Hypertension, commonly known as high blood pressure, is a prevalent medical condition characterized by persistently elevated blood pressure levels. There are two main types of hypertension: primary (essential) hypertension and secondary hypertension. Primary hypertension, the most common form, has multifactorial causes, including genetics, lifestyle factors, and aging. An underlying medical condition causes secondary hypertension. The condition can be classified broadly into Elevated, Stage 1, Stage 2, and hypertensive crisis.

Hypertension Diagnosis and Treatment Algorithm

Hypertension diagnosis involves measuring a person’s blood pressure to determine if it exceeds the normal range. A healthcare professional typically uses a blood pressure cuff, sphygmomanometer, or automated blood pressure monitoring device to obtain accurate readings. Diagnosing hypertension presents challenges due to its silent nature, with no noticeable symptoms in the early stages, leading to underdiagnosis.

The treatment of hypertension usually combines lifestyle modifications and medication. Lifestyle changes encompass adopting a low-sodium, healthy diet, engaging in regular physical exercise, maintaining a healthy weight, moderating alcohol intake, and quitting smoking. Medications can be prescribed to reduce blood pressure, including diuretics, beta-blockers, ACE inhibitors, ARBs, or calcium channel blockers. By implementing these approaches, individuals with hypertension can effectively manage their condition and lower the risk of complications. Adherence to lifestyle modifications and medication can be challenging due to various factors like time constraints, lack of motivation, and the forgetful nature of the patient.

Hypertension Epidemiology

The Hypertension epidemiology section provides insights into the historical and current Hypertension patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, its trends, and assumptions undertaken.

The epidemiology section of the Hypertension market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

Key Findings

According to Centers for Disease Control and Prevention (2021), nearly half of adults in the United States (47%) have hypertension, defined as a systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg or are taking medication for hypertension.

According to World Health Organization (2023), the prevalence of hypertension shows regional and income group variations, with the WHO Region of the Americas exhibiting the lowest prevalence of hypertension at 18%. Different regions and countries display varying rates of hypertension.

According to Eurostat data, 22% of people in Europe have high blood pressure, whereas country-wise data show a varied trend. As per the NHS Digital (2019), over 28% of adults have hypertension in the UK. Additionally, around 33% of the adult German population is affected by hypertension, a considerable burden on the healthcare system (Neuhauser et al., 2015).

According to Okui et al. (2022), the current prevalence of hypertension is approximately 30% and 20%, respectively, for men and women aged 20 or more years in Japan.

 Get a more detailed overview of How Hypertension Epidemiology will evolve in the upcoming years: Hypertension Epidemiology Forecast

Hypertension Market Outlook

The current treatment for hypertension involves a combination of lifestyle modifications and medications. Lifestyle modifications include adopting a healthy diet low in sodium, engaging in regular physical exercise, maintaining a healthy weight, limiting alcohol consumption, and quitting smoking. Therapeutic classes of drugs include diuretics, beta-blockers, ACE inhibitors, ARBs, calcium channel blockers, and other antihypertensive drugs. These therapies may be used alone or in combination with each other.

As per a study by An et al.(2021), around one-third of the overall patients were prescribed ACE inhibitor and thiazide diuretic combination, with 22% receiving ACE inhibitor monotherapy. Beta-blockers were also administered to one-tenth of the hypertension patients. Another study underscores the higher usage of ACE inhibitors based on 2016 administrative claims data from the US (Bandhakavi et al., 2020). Generally, there has been a shift in the prescriptions during treatment from one drug to another or some additions to the existing one.

Multiple therapies are under development aiming to improve the management or to cater to the treatment-resistant cases of hypertension. These drugs will likely hit the market during the forecast period of 2023–2032.

According to DelveInsight, the Hypertension market in the 7MM is expected to significantly change during the study period 2019–2032.

While the hypertension market has generally shown a positive trend, certain factors could potentially contribute to a decline involving low compliance with antihypertensives or poor access to newer medications.

Hypertension Recent Developments

• In April 2025, Orchestra BioMed Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation (BDD) for its atrioventricular interval modulation (AVIM) therapy. This designation recognizes the potential of AVIM therapy to address uncontrolled hypertension and cardiovascular risk in a U.S. population of over 7.7 million patients. The therapy is currently being studied in the BACKBEAT global pivotal study, a strategic collaboration with Medtronic.
• In March 2025, SCIENTURE HOLDINGS, INC. announced it completed a draw on its Equity Line of Credit (ELOC) to support the commercial launch of Arbli™ (losartan potassium) Oral Suspension. The company also temporarily suspended further ELOC draws for the next 30 trading days or until its stock reaches $10 per share, whichever comes first.

Hypertension Drug Chapters

Marketed Hypertension Drugs

The range of medications used in the treatment of high blood pressure are mainly available as generics. Generic versions of commonly prescribed antihypertensive drugs are available for the classes, including diuretics (e.g., hydrochlorothiazide), beta-blockers (e.g., metoprolol), ACE inhibitors (e.g., lisinopril), ARBs (e.g., losartan), and calcium channel blockers (e.g., amlodipine). These generic medications contain the same active ingredients as their brand-name counterparts but are typically sold at lower prices.

Note: Detailed marketed therapies assessment will be provided in the final report.

Emerging Hypertension Drugs

The currently available treatments for hypertension aim to mitigate the complications associated with the condition. The hypertension market dynamics are expected to change, primarily due to increased healthcare spending worldwide. Hypertension companies in the market such as Mineralys Therapeutics Inc, CinCor Pharma, and others are actively involved in developing Hypertension treatments.

Lorundrostat: Mineralys Therapeutics Inc.

Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled and resistant hypertension. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. The drug has recently completed a Phase II clinical trial.

BAXDROSTAT: CinCor Pharma

Baxdrostat is an investigational drug that selectively inhibits aldosterone synthase, a treatment target in hypertension. The drug is currently in Phase II of its clinical development.

Explore more about the emerging therapies and key companies actively working in the market: Hypertension Pipeline Insights

Hypertension Market Segmentation

DelveInsight’s ‘Hypertension Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a detailed outlook of the current and future Hypertension market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Hypertension Market Size by Countries

The total Hypertension market size is analyzed for individual countries (the United States Market, EU4 (Germany, France, Italy, and Spain) and the UK market, and Japan). The United States accounted for a larger portion of the 7MM market for hypertension in 2022 due to the high prevalence of the condition and the higher cost of treatments. This dominance is predicted to continue with the potential early entry of new products.

Hypertension Market Size by Therapies

A wide range of medications are available for the treatment of hypertension, belonging to different classes and acting through diverse mechanisms to lower blood pressure. These medications include diuretics, which assist in reducing fluid volume and sodium levels in the body; beta-blockers block the effects of adrenaline on the heart and blood vessels; ACE inhibitors inhibit the production of angiotensin II, a hormone that causes blood vessels to constrict; ARBs blocks the action of angiotensin II on blood vessels; calcium channel blockers promotes relaxation of blood vessels and reduce strain on the heart; and direct renin inhibitors inhibits the enzyme renin involved in the production of angiotensin II.

Medication selection is determined by factors such as an individual’s blood pressure levels, coexisting medical conditions, and potential side effects.

There are promising emerging drugs that might fall under the existing classes or have novel mechanisms of action which are likely to have a decent contribution to the market when approved.

Note: Detailed market segment assessment will be provided in the final report.

Hypertension Drugs Uptake

This section focuses on the sales uptake of potential Hypertension drugs that have recently launched or are anticipated to be launched in the Hypertension market between 2019 and 2032. It estimates the market penetration of Hypertension drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Hypertension market.

The emerging Hypertension therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Hypertension market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on hypertension.

Hypertension Market Access and Reimbursement

DelveInsight’s ‘Hypertension – Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a descriptive overview of the market access and reimbursement scenario of hypertension.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current Hypertension market trends and fulfill gaps in secondary findings, we interview KOLs and SMEs’ working in the Hypertension domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Hypertension market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the hypertension unmet needs.

Hypertension: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as The George Washington University in the US, and the University of Milano-Bicocca, Milan in Italy.

“Hypertension affects a substantial portion of the population, with its prevalence increasing due to aging populations, sedentary lifestyles, and unhealthy dietary habits.”

“First-line medications frequently prescribed for hypertension management include diuretics (such as hydrochlorothiazide, a thiazide diuretic), ACE inhibitors, ARBs, and calcium channel blockers.”

Note: Detailed assessment of KOL Views will be provided in the full hypertension report.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Hypertension Market using various Competitive Intelligence tools, including SWOT analysis, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Hypertension Pipeline Development Activities

The report provides insights into therapeutic candidates in Phase II and III stages. It also analyses Hypertension Companies involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers collaborations, acquisition and merger, licensing, patent details, and other information for emerging Hypertension therapies.

Hypertension Report Insights

• Hypertension Patient Population
• Therapeutic Approaches
• Hypertension Pipeline Analysis
• Hypertension Market Size and Trends
• Hypertension Market Opportunities
• Impact of Upcoming Therapies

Hypertension Report Key Strengths

• 10 years Forecast
• 7MM Coverage
• Hypertension Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Hypertension Market
• Hypertension Drugs Uptake

Hypertension Report Assessment

• Hypertension Current Treatment Practices
• Unmet Needs
• Hypertension Pipeline Product Profiles
• Hypertension Market Attractiveness

Key Questions

• What are the key findings of the market across 7MM, and what country will have the largest Hypertension market size during the forecast period (2023–2032)?
• At what CAGR is the Hypertension market, and is epidemiology expected to grow in the 7MM during the forecast period (2023–2032)?
• What is the current market size for hypertension treatment (2023–2032)?
• What are the key drivers of growth in the hypertension market (2023–2032)?
• Which regions or countries have the highest prevalence of hypertension (2023–2032)?
• What are the most commonly prescribed medications for hypertension (2023–2032)?
• Are there any emerging therapies in the hypertension market (2023–2032)?
• What factors contribute to the increasing demand for hypertension treatment (2023–2032)?
• Are regulatory or reimbursement challenges affecting the hypertension market (2023–2032)?
• How do lifestyle modifications impact the demand for hypertension medications (2023–2032)?
• Are there any market barriers or challenges hindering the growth of the hypertension market (2023–2032)?
• What strategies are pharmaceutical companies adopting to capture a larger share of the hypertension market (2023–2032)?
• What are the present unmet needs associated with hypertension treatment?